





Date: 14 January 2023

То	То
BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	Exchange Plaza
Dalal Street	Bandra Kurla Complex
Mumbai- 400001	Bandra (E)
	Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)

Dear Sir/Madam,

This is further to our letter dated 10 January 2023 intimating about the date of the Board of Directors Meeting to, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the guarter ended 31 December 2022.

We wish to inform that pursuant to regulation 30 and other applicable regulations, if any, of the SEBI LODR, 2015 the Company will hold a conference call for analysts and investors on Tuesday, 17 January 2023. The details of the said call are attached herewith and also available on Company's website.

Thanking you.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary and Compliance Officer
ICSI Membership No.: A26493

Encl.:a/a



The Senior Management Team of

Eris Lifesciences Limited

Cordially invites you to its

Earnings Conference Call

To discuss the financial and operational performance for

Q3 & 9M FY 23

Day/Date: Tuesday, 17th January 2023

Time: 5:30 PM, IST

Option 1: Express Join with Diamond Pass ™

Pre-register with the below link and join without waiting for the operator:

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9558554&linkSecurityString=2e8ed6fcb0

Option 2: Join through below Dial-In Numbers

Access Numbers		
Primary Number:	+91 22 6280 1472	
	+91 22 7115 8839	

> Sweden: 008 001 424 3444 Thailand: 0 018 001 424 3444

USA: 1866 746 2133

Singapore: 800 101 2045 Hong Kong: 800 964 448

South Korea: 0 018 001 424 3444

0 808 101 1573

UK:

We look forward to your participation

RSVP:

Kruti Raval: kruti@erislifesciences.com